There may be some diamonds-in-the-rough among pharmaceutical consolidators and hospital chains.
Insiders have an edge in this complex sector, so it's worth checking them out.
With weak chart patterns and a quantitative downgrade, longs should protect their positions.
My goal is to make sure I wrap up 2016 at highs.
The company has a lucrative end market and sufficient funding in place.
It's got several newly launched promising drugs, a number of late-stage prospects and strong financials.
Egalet, Portola Pharmaceuticals and Amicus Therapeutics hold promise for improvement.
The euphoria has calmed down, and if stocks can consolidate, we will have some better entry points.
Heavier volume on down days is a subtle sign that traders and investors want 'out.'
Here's why Gilead and Celgene should finally reward their shareholders next year.

Columnist Conversations

Nice move in GPS today. The stock is up 2.7% late in the session and is holding above last month's peak($24.93...
I have read her book, 'Dare to Serve' and have seen her interviewed multiple times by Jim Cramer on Mad Money....


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.